Pfizer Dips On BMO Downgrade

AP Margins at pharmaceutical giant Pfizer could face currency pressure just as sales of major drugs slow. So concludes BMO Capital Markets today in a downgrade report, which sent shares of Pfizer (PFE) down nearly 1% to $29.86. BMO reduced its rating to Market Perform from Outperform, and lowered its price target to $31 from $34. Analyst [...]